Two R&D pros map a PhIII game plan with $65M round and a castoff from Pfizer
Can Corey Fishman and Michael Dunne come back and repeat the success they had with Durata?
A little more than two years after they succeeded …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
